Ran Neuner

Neuner explicitly states Coinbase (COIN) is his "biggest holding by far" and he also holds a significant position in Robinhood (HOOD). In a market where specific token winners are uncertain ("I don't know which tokens will be quantum resistant"), the infrastructure plays are the safest bet. If the crypto industry survives, trading volume must flow through regulated venues. COIN specifically captures the "Agentic Economy" via its Base L2 chain and custody services. LONG as a defensive "pick and shovel" play on the crypto industry. Regulatory conflict between Coinbase CEO Brian Armstrong and the US Treasury (specifically Scott Bessent in this 2026 timeline).

Gold has decoupled from Bitcoin and is hitting all-time highs (cited as $5,200 in this future timeline) while Bitcoin falters. Sovereign buying (specifically the People's Bank of China) is driving Gold. Since China dumps US Treasuries and cannot buy Bitcoin (banned), Gold has become the *actual* recipient of the "Store of Value" capital flight. LONG as the winner of the current macro "fear" trade. Reversal of Chinese monetary policy or a sudden rotation back into risk-on digital assets.

Neuner explicitly states Coinbase (COIN) is his "biggest holding by far" and he also holds a significant position in Robinhood (HOOD). In a market where specific token winners are uncertain ("I don't know which tokens will be quantum resistant"), the infrastructure plays are the safest bet. If the crypto industry survives, trading volume must flow through regulated venues. COIN specifically captures the "Agentic Economy" via its Base L2 chain and custody services. LONG as a defensive "pick and shovel" play on the crypto industry. Regulatory conflict between Coinbase CEO Brian Armstrong and the US Treasury (specifically Scott Bessent in this 2026 timeline).

Neuner mentions he told people to invest in ImmunityBio (IBRX) because they "may have just found a cure for cancer." He uses this to illustrate the necessity of a strong "Why" for investing. Unlike Bitcoin's currently muddied narrative, a biotech breakthrough offers a clear, compelling reason for capital allocation. LONG based on the "strong narrative" thesis. Clinical trial failures or regulatory rejections (standard biotech binary risk).